I noticed some in this recent cohort had 177lu and 255ac. I can see how this would've played a part in how well patients would've responded to cu67. If 255ac isn't approved, why would the FDA consider having 255ac as a prereq for P3?
Despite all this, 44% had PSA over 50% on a single dose(pluvicto was ~46%).
Ann: Theranostic prostate cancer trial advances to multi-dose, page-21
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.80 |
Change
0.230(4.13%) |
Mkt cap ! $1.735B | |||
| Open | High | Low | Value | Volume |
| $5.68 | $5.88 | $5.68 | $1.475M | 254.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 1489 | $5.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.80 | 2076 | 2 |
View Market Depth
| Last trade - 10.38am 12/07/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |